Three preprints propose directly estimating chemotherapy benefit instead of repurposing genomic risk assays
kjgeras · x · 2026-09-14
Oncology researcher kjgeras announced 3 preprints arguing that cancer aggressiveness and the benefit from escalated treatment are different estimands. Genomic assays built decades ago target the former but were repurposed for the latter. The new work estimates the benefit of escalated treatment directly.
More from Research
- ELLIS x UniReps talk: why distinct learning processes yield similar representations — ClementineDomi6 · 2026-10-30
- Physicist calls OpenAI's Navier-Stokes solution physically meaningless despite loophole win — GaryMarcus · 2026-10-30
- Anthropic paper: 0.1% pretraining poison plants RCE backdoor in 4B CLI agent — omarsar0 · 2026-10-30
- CopeNLU presents 7 papers at EMNLP 2026 on bias, alignment, explainability — IAugenstein · 2026-10-30
- Two-stage 3D ResNet pipeline detects neonatal brain pathologies from MRI with 0.919 AUC — Dr_Alex_Crimi · 2026-10-30
- 40 years of putting new neurons into the CNS: why so slow, and can AI accelerate it? — patrickmineault · 2026-10-30